IRON

Disc Medicine Inc

79.48

Oct 20 • 3:59 PM ET +0.55 (0.70%)

78.81

Aftermarket • 6:18 PM ET -0.67 (-0.84%)

Healthcare Biotechnology USA Mid NASD

Oct 19, 4:05 PMDisc Medicine announces $350 million underwritten offering of common stock and pre-funded warrants with 30-day $52.5 million underwriter option

Peers: PTGX AGIO SLN IONS GERN DMRA INCY RIGL FULC KROS

| Held by: VTI XBI IWM VXF IWO IBB SCHA DFAS VTWO DFAC

Scroll to Statements

Index	RUT
Market Cap	3.05B
Enterprise Value	2.39B
Income	-245.89M
Sales	0.00M
Book/sh	16.80
Cash/sh	18.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	155
IPO	Aug 12, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.73
P/C	4.25
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	24.14
Current Ratio	24.14
Debt/Eq	0.09
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	-6.58
EPS next Y	-6.72
EPS next Q	-1.63
EPS this Y	-5.21%
EPS next Y	-6.29%
EPS next 5Y	6.70%
EPS past 3/5Y	48.90% 25.96%
Sales past 3/5Y	- -
EPS Y/Y TTM	-47.00%
Sales Y/Y TTM	-
EPS Q/Q	2.44%
Sales Q/Q	-
Earnings	Jul 30 BMO
EPS/Sales Surpr.	10.07% -

Insider Own	26.67%
Insider Trans	-2.26%
Inst Own	97.39%
Inst Trans	1.77%
ROA	-35.12%
ROE	-39.08%
ROIC	-34.89%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	24.59%
SMA50	11.06%
SMA200	12.48%
Trades

Shs Outstand	38.35M
Shs Float	28.15M
Short Float	25.83%
Short Ratio	11.79
Short Interest	7.27M
52W High	99.50 -20.12%
52W Low	40.00 98.70%
Volatility	7.13% 4.93%
ATR (14)	4.42
RSI (14)	70.12
Beta	0.99
Rel Volume	3.58
Avg Volume	616.91K
Volume	2,206,173

Perf Week	40.42%
Perf Month	16.05%
Perf Quarter	6.94%
Perf Half Y	15.06%
Perf YTD	0.09%
Perf Year	-8.82%
Perf 3Y	84.58%
Perf 5Y	117.16%
Perf 10Y	-
Recom	1.00
Target Price	121.50
Prev Close	78.93
Price	79.48
Change %	0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Resumed	Stifel	Buy	$125
Jul-21-25	Initiated	Truist	Buy	$86
Jul-03-25	Resumed	Morgan Stanley	Overweight	$85
Jun-11-25	Resumed	Raymond James	Strong Buy	$89
Feb-27-25	Initiated	TD Cowen	Buy
Nov-05-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$85
Nov-04-24	Upgrade	Raymond James	Outperform → Strong Buy	$66 → $110
Oct-23-24	Initiated	Jefferies	Buy	$89
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight	$75
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform	$40
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $65
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy	$50 → $75
Jun-07-23	Initiated	H.C. Wainwright	Buy	$55
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

Show Previous Ratings

Today 08:59AM	A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
Oct-19-26 04:01PM	Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +38.86%
12:27PM	Discs once-spurned rare disease drug to get a second chance at approval (BioPharma Dive)
12:22PM	?? Under the Radar: Disc Shares Jump as Pill for Sunlight Disorder Succeeds in Study (The Wall Street Journal)
11:28AM	Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes (Barrons.com)
10:52AM	Loading…
10:52AM	Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints (Proactive)
08:48AM	Disc Medicine Shares Rise 60% After Phase 3 Bitopertin Trial Meets Primary and Secondary Endpoints (InvestorsHub)
07:55AM	Disc Medicine surge 60% on positive Phase 3 trial for rare sunlight disorder (Investing.com)
07:00AM	Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Oct-18-26 05:00PM	Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Sep-09-26 07:25PM	Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting (GlobeNewswire)
Sep-02-26 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-31-26 06:00PM	Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting (GlobeNewswire)
Jul-30-26 08:30AM	Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.52%
Jun-12-26 08:30AM	Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting (GlobeNewswire)
08:30AM	Loading…
Jun-09-26 08:30AM	Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria (GlobeNewswire)
Jun-02-26 08:00AM	Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.52%
Jun-01-26 08:30AM	Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients (GlobeNewswire)
May-12-26 09:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress (GlobeNewswire)
May-11-26 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-05-26 08:30AM	Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-21-26 10:00AM	Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-26-26 04:30PM	Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria (GlobeNewswire)
Mar-09-26 01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
Mar-04-26 02:55AM	What 3 recent FDA rejections reveal about shifts inside the agency (Pharma Voice) -5.07%
Feb-26-26 08:30AM	Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-26 04:27PM	Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 (MarketBeat)
Feb-18-26 05:35AM	FDA accepts BMS protein degrader for review; Disc rare disease drug rejected (BioPharma Dive)
Feb-17-26 05:54AM	FDA Delays Disc Medicine's Rare Disease Drug (Benzinga) +17.19%
06:20AM	Loading…
Feb-16-26 06:20AM	FDA issues complete response letter to Disc Medicine's bitopertin NDA (Pharmaceutical Business Review)
Feb-13-26 03:04PM	Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP (GlobeNewswire) -21.91%
Jan-28-26 09:55AM	Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade (Zacks)
Jan-16-26 01:34PM	Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action (Benzinga)
Jan-15-26 02:09PM	State Street's crypto push, FDA delays review of Eli Lilly GLP-1 (Yahoo Finance Video) -7.84%
08:26AM	FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (Benzinga)
Jan-13-26 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Jan-12-26 04:30PM	Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer (GlobeNewswire)
08:30AM	Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 (GlobeNewswire)
Jan-07-26 08:30AM	Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-25 05:14PM	Seadrill, Vestis, Mastercraft Boat, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-11-25 07:44AM	Leering Partners Lifts Disc Medicine, Inc. (IRON) Following EPP Drug NDA Application (Insider Monkey)
Dec-09-25 12:20AM	This is Why Disc Medicine, Inc. (IRON) is a Buy on Wall Street (Insider Monkey)
Dec-06-25 08:00AM	Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-06-25 08:30AM	Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-25 09:00AM	Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-25 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 12:00PM	What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-22-25 09:55AM	Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect? (Zacks)
Oct-21-25 12:14AM	Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-20-25 08:25AM	FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks (GuruFocus.com)
07:00AM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:30AM	Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones (GlobeNewswire)
Oct-17-25 10:17AM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily) +20.95%
09:00AM	Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-16-25 05:35PM	Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Sep-30-25 08:30AM	Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Aug-27-25 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 05:16PM	Rapid7, Residio Tech, and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-07-25 08:30AM	Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-25 10:05AM	Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 (Insider Monkey)
Jul-22-25 09:15AM	OrbiMed Promotes Mona Ashiya to General Partner (PR Newswire)
Jul-21-25 08:00AM	Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 (GlobeNewswire)
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT (Insider Monkey)
Jun-24-25 05:42PM	Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target (Insider Monkey) +6.42%
Jun-15-25 05:42AM	Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating (Insider Monkey)
Jun-12-25 07:30AM	Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress (GlobeNewswire)
Jun-11-25 09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
May-28-25 04:01PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 08:00AM	Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-07-25 08:00AM	Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-25 08:00AM	Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) (GlobeNewswire)
Apr-09-25 07:13AM	Disc Medicine: Forging Ahead In Hematology (Seeking Alpha) +12.89%
Mar-26-25 09:39PM	Is Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 12:00PM	All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy (Zacks)
Mar-03-25 09:55AM	Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know (Zacks)
Feb-27-25 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-25 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-25 09:55AM	Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-23-25 08:28AM	Disc raises $225.5m as it eyes approval of rare skin disorder drug (Pharmaceutical Technology)
Jan-22-25 09:35PM	Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-21-25 04:01PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
07:45AM	Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission (GlobeNewswire)
Jan-20-25 07:00PM	Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Jan-17-25 04:00PM	Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-10-25 09:00AM	Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 (GlobeNewswire) -5.27%
Dec-09-24 12:00PM	Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-24 08:00PM	Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-24 06:10AM	Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-13-24 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 08:00AM	Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 10:38AM	Disc Medicine secures $200m financing to support trials (Clinical Trials Arena)
Nov-08-24 08:30AM	Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. (GlobeNewswire)
Nov-05-24 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +11.20%
Nov-04-24 01:44PM	Disc teases potential NDA for rare skin disorder drug (Pharmaceutical Technology) +23.59%
07:50AM	Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval (GlobeNewswire)
Nov-01-24 04:01PM	Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire) +5.15%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Atlas Venture Opportunity Fund	Shareholder	Oct 20 '26	Proposed Sale	78.93	2,388	188,485		Oct 20 05:16 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 20 '26	Proposed Sale	78.93	2,869	226,450		Oct 20 05:16 PM
Atlas Venture Fund X, LP	Shareholder	Oct 20 '26	Proposed Sale	78.93	6,965	549,747		Oct 20 05:15 PM
Atlas Venture Fund XII, LP	Shareholder	Oct 20 '26	Proposed Sale	78.93	55	4,341		Oct 20 05:15 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 19 '26	Proposed Sale	56.84	4,942	280,903		Oct 19 04:44 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 19 '26	Proposed Sale	56.84	5,937	337,459		Oct 19 04:44 PM
Atlas Venture Fund X, LP	Shareholder	Oct 19 '26	Proposed Sale	56.84	14,414	819,292		Oct 19 04:44 PM
Atlas Venture Fund XII, LP	Shareholder	Oct 19 '26	Proposed Sale	56.84	115	6,537		Oct 19 04:43 PM
Quisel John D	Chief Executive Officer	Sep 15 '26	Option Exercise	1.01	36,000	36,360	262,064	Sep 16 06:44 PM
Bitterman Kevin	Director	Sep 11 '26	Option Exercise	45.07	27,136	1,223,144	27,136	Sep 15 04:30 PM
Bitterman Kevin	Director	Sep 11 '26	Sale	70.11	27,136	1,902,505	0	Sep 15 04:30 PM
KEVIN J BITTERMAN	Officer	Sep 11 '26	Proposed Sale	70.11	27,136	1,902,505		Sep 11 04:11 PM
Bitterman Kevin	Director	Sep 04 '26	Sale	79.96	1,689	135,052	13,427	Sep 09 04:23 PM
Atlas Venture Fund XII, LP	Shareholder	Sep 04 '26	Proposed Sale	79.37	18	1,429		Sep 04 04:36 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 04 '26	Proposed Sale	79.37	759	60,242		Sep 04 04:35 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 04 '26	Proposed Sale	79.37	912	72,385		Sep 04 04:34 PM
Atlas Venture Fund X, LP	Shareholder	Sep 04 '26	Proposed Sale	79.37	2,212	175,566		Sep 04 04:32 PM
Bitterman Kevin	Director	Sep 02 '26	Sale	80.17	49,164	3,941,495	13,499	Sep 03 05:43 PM
Bitterman Kevin	Director	Sep 03 '26	Sale	79.98	5,203	416,136	13,445	Sep 03 05:43 PM
Bitterman Kevin	Director	Sep 01 '26	Sale	79.95	129	10,314	14,012	Sep 03 05:43 PM
Atlas Venture Fund XII, LP	Shareholder	Sep 03 '26	Proposed Sale	80.05	54	4,323		Sep 03 05:09 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 03 '26	Proposed Sale	80.05	2,339	187,237		Sep 03 05:08 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 03 '26	Proposed Sale	80.05	2,810	224,940		Sep 03 05:08 PM
Atlas Venture Fund X, LP	Shareholder	Sep 03 '26	Proposed Sale	80.05	6,822	546,101		Sep 03 05:08 PM
Atlas Venture Fund XII, LP	Shareholder	Sep 02 '26	Proposed Sale	78.67	513	40,358		Sep 02 04:47 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 02 '26	Proposed Sale	78.67	22,099	1,738,528		Sep 02 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 02 '26	Proposed Sale	78.67	26,552	2,088,846		Sep 02 04:45 PM
Atlas Venture Fund X, LP	Shareholder	Sep 02 '26	Proposed Sale	78.67	64,460	5,071,068		Sep 02 04:44 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Aug 25 '26	Option Exercise	13.50	8,796	118,746	63,120	Aug 26 08:10 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Aug 24 '26	Option Exercise	13.50	300	4,050	54,624	Aug 26 08:10 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Aug 25 '26	Sale	83.12	8,796	731,092	54,324	Aug 26 08:10 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Aug 24 '26	Sale	82.53	300	24,760	54,324	Aug 26 08:10 PM
Quisel John D	Chief Executive Officer	Aug 17 '26	Option Exercise	13.50	33,000	445,500	259,064	Aug 18 06:56 PM
Quisel John D	Chief Executive Officer	Aug 17 '26	Sale	79.15	33,000	2,611,982	226,064	Aug 18 06:56 PM
JOHN QUISEL	Director	Aug 17 '26	Proposed Sale	78.84	33,000	2,601,720		Aug 17 04:31 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Aug 12 '26	Option Exercise	13.50	804	10,854	55,128	Aug 14 07:14 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Aug 12 '26	Sale	82.64	804	66,445	54,324	Aug 14 07:14 PM
Khara Rahul	Chief Legal Officer	Aug 06 '26	Option Exercise	14.69	5,000	73,450	57,324	Aug 07 05:32 PM
Khara Rahul	Chief Legal Officer	Aug 06 '26	Sale	80.00	5,000	400,000	52,324	Aug 07 05:32 PM
RAHUL KHARA	Officer	Aug 06 '26	Proposed Sale	78.91	5,000	394,550		Aug 06 04:27 PM
Quisel John D	Chief Executive Officer	Jul 13 '26	Option Exercise	10.68	33,000	352,374	259,064	Jul 14 06:32 PM
Quisel John D	Chief Executive Officer	Jul 13 '26	Sale	74.96	33,000	2,473,780	226,064	Jul 14 06:32 PM
JOHN QUISEL	Director	Jul 13 '26	Proposed Sale	76.59	33,000	2,527,470		Jul 13 04:34 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jul 07 '26	Option Exercise	13.50	100	1,350	54,424	Jul 09 07:35 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jul 07 '26	Sale	82.50	100	8,250	54,324	Jul 09 07:35 PM
JONATHAN YU	Officer	Jul 07 '26	Proposed Sale	77.01	10,000	770,100		Jul 07 04:32 PM
Khara Rahul	Chief Legal Officer	Jun 29 '26	Option Exercise	14.69	1,649	24,224	53,822	Jun 30 05:49 PM
Khara Rahul	Chief Legal Officer	Jun 26 '26	Option Exercise	14.69	851	12,501	53,024	Jun 30 05:49 PM
Khara Rahul	Chief Legal Officer	Jun 29 '26	Sale	75.00	1,649	123,675	52,173	Jun 30 05:49 PM
Khara Rahul	Chief Legal Officer	Jun 26 '26	Sale	75.00	851	63,825	52,173	Jun 30 05:49 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jun 26 '26	Option Exercise	13.50	300	4,050	54,624	Jun 30 05:45 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jun 26 '26	Sale	72.50	300	21,750	54,324	Jun 30 05:45 PM
RAHUL KHARA	Officer	Jun 26 '26	Proposed Sale	70.16	2,500	175,400		Jun 26 04:32 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jun 22 '26	Option Exercise	13.50	9,700	130,950	64,024	Jun 24 08:34 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jun 22 '26	Sale	72.66	9,700	704,795	54,324	Jun 24 08:34 PM
Khara Rahul	Chief Legal Officer	Jun 18 '26	Option Exercise	14.69	7,500	110,175	59,673	Jun 23 05:21 PM
Khara Rahul	Chief Legal Officer	Jun 18 '26	Sale	70.22	7,500	526,661	52,173	Jun 23 05:21 PM
Quisel John D	Chief Executive Officer	Jun 18 '26	Option Exercise	9.86	34,000	335,240	260,064	Jun 23 05:16 PM
Quisel John D	Chief Executive Officer	Jun 18 '26	Sale	70.21	34,000	2,387,296	226,064	Jun 23 05:16 PM
JONATHAN YU	Officer	Jun 22 '26	Proposed Sale	70.79	10,000	707,900		Jun 22 04:47 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jun 16 '26	Option Exercise	9.86	18,612	183,514	72,936	Jun 18 04:43 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Jun 16 '26	Sale	69.19	18,612	1,287,801	54,324	Jun 18 04:43 PM
JOHN QUISEL	Director	Jun 18 '26	Proposed Sale	70.21	34,000	2,387,140		Jun 18 04:27 PM
RAHUL KHARA	Officer	Jun 18 '26	Proposed Sale	70.21	7,500	526,575		Jun 18 04:27 PM
JONATHAN YU	Officer	Jun 16 '26	Proposed Sale	70.09	18,612	1,304,515		Jun 16 04:40 PM
Savage William Jacob	Chief Medical Officer	Apr 13 '26	Sale	66.38	5,731	380,449	79,480	Apr 15 05:05 PM
Franchi Jean M.	Chief Financial Officer	Apr 14 '26	Sale	69.24	6,257	433,234	64,333	Apr 15 04:53 PM
Franchi Jean M.	Chief Financial Officer	Apr 13 '26	Sale	69.00	400	27,600	70,590	Apr 15 04:53 PM
WILLIAM SAVAGE	Officer	Apr 13 '26	Proposed Sale	66.32	5,731	380,080		Apr 13 04:37 PM
Savage William Jacob	Chief Medical Officer	Mar 02 '26	Sale	65.88	7,378	486,069	85,211	Mar 04 04:55 PM
WILLIAM SAVAGE	Officer	Mar 02 '26	Proposed Sale	66.62	7,378	491,522		Mar 02 04:32 PM
Franchi Jean M.	Chief Financial Officer	Feb 25 '26	Sale	69.06	353	24,377	70,990	Feb 27 04:49 PM
JEAN FRANCHI	Officer	Feb 25 '26	Proposed Sale	66.20	7,010	464,062		Feb 25 04:29 PM
Franchi Jean M.	Chief Financial Officer	Feb 18 '26	Sale	65.47	7,081	463,573	71,343	Feb 19 05:42 PM
Franchi Jean M.	Chief Financial Officer	Feb 17 '26	Sale	62.86	4,075	256,154	78,424	Feb 19 05:42 PM
JEAN FRANCHI	Officer	Feb 18 '26	Proposed Sale	65.57	7,081	464,301		Feb 18 04:41 PM
Khara Rahul	Chief Legal Officer	Feb 17 '26	Sale	62.86	2,853	179,340	52,173	Feb 17 09:20 PM
Stephenson Pamela	Chief Commercial Officer	Feb 17 '26	Sale	62.86	5,531	347,679	80,998	Feb 17 09:15 PM
Savage William Jacob	Chief Medical Officer	Feb 17 '26	Sale	62.86	3,256	204,672	92,589	Feb 17 09:09 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Feb 17 '26	Sale	62.86	3,231	203,101	54,324	Feb 17 09:05 PM
Quisel John D	Chief Executive Officer	Feb 17 '26	Sale	62.86	13,264	833,775	226,064	Feb 17 09:03 PM
Khara Rahul	Officer	Feb 17 '26	Proposed Sale	55.95	2,853	159,625		Feb 17 08:57 PM
Stephenson Pamela	Officer	Feb 17 '26	Proposed Sale	55.95	5,531	309,459		Feb 17 08:54 PM
Savage William Jacob	Officer	Feb 17 '26	Proposed Sale	55.95	3,256	182,173		Feb 17 08:51 PM
Yu Jonathan Yen-Wen	Officer	Feb 17 '26	Proposed Sale	55.95	3,231	180,774		Feb 17 08:46 PM
Franchi Jean M.	Officer	Feb 17 '26	Proposed Sale	55.95	4,075	227,996		Feb 17 08:43 PM
Quisel John D	Officer	Feb 17 '26	Proposed Sale	55.95	13,264	742,121		Feb 17 08:38 PM
Khara Rahul	Chief Legal Officer	Jan 20 '26	Option Exercise	13.50	1,000	13,500	38,793	Jan 21 06:55 PM
Khara Rahul	Chief Legal Officer	Jan 20 '26	Sale	69.74	1,000	69,740	37,793	Jan 21 06:55 PM
Khara Rahul	Chief Legal Officer	Jan 02 '26	Option Exercise	13.50	6,500	87,750	44,293	Jan 05 08:02 PM
Khara Rahul	Chief Legal Officer	Jan 02 '26	Sale	78.69	6,500	511,472	37,793	Jan 05 08:02 PM
RAHUL KHARA	Officer	Jan 02 '26	Proposed Sale	79.41	7,500	595,575		Jan 02 04:30 PM
Savage William Jacob	Chief Medical Officer	Dec 22 '25	Option Exercise	9.97	3,143	31,350	78,845	Dec 29 08:50 PM
Quisel John D	Chief Executive Officer	Dec 19 '25	Option Exercise	1.01	12,300	12,423	184,128	Dec 19 06:16 PM
Bitterman Kevin	Director	Dec 17 '25	Sale	91.47	754	68,968	14,013	Dec 18 06:14 PM
AI DMI LLC	Affiliate	Dec 17 '25	Proposed Sale	87.49	50	4,374		Dec 17 07:48 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 17 '25	Proposed Sale	91.47	148	13,538		Dec 17 05:08 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 17 '25	Proposed Sale	91.47	213	19,483		Dec 17 05:07 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 17 '25	Proposed Sale	91.47	393	35,948		Dec 17 05:06 PM
Atlas Venture Fund X, LP	Shareholder	Dec 17 '25	Proposed Sale	91.47	818	74,822		Dec 17 05:05 PM

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Executive ChairmanDr. Donald William Nicholson Ph.D.

J.D.Dr. John D. Quisel Esq.

Chief Financial OfficerMs. Jean M. Franchi CPA

Chief Opearating OfficerMr. Jonathan Yu M.B.A.

Ph.D.Dr. William Jacob Savage M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IRON

Disc Medicine Inc

Upgrade your Finviz experience